Adverse drug reactions (ADRs) are a major obstacle to drug development, and some of these, including hypersensitivity reactions to the HIV reverse transcriptase inhibitor abacavir (ABC), are associated with HLA alleles, particularly HLA-B*57:01. However, not all HLA-B*57:01+ patients develop ADRs, suggesting that in addition to the HLA genetic risk, other factors may influence the outcome of the response to the drug. To study HLA-linked ADRs in vivo, we generated HLA-B*57:01–Tg mice and show that, although ABC activated Tg mouse CD8+ T cells in vitro in a HLA-B*57:01–dependent manner, the drug was tolerated in vivo. In immunocompetent Tg animals, ABC induced CD8+ T cells with an anergy-like phenotype that did not lead to ADRs. In contrast, in vivo depletion of CD4+ T cells prior to ABC administration enhanced DC maturation to induce systemic ABC-reactive CD8+ T cells with an effector-like and skin-homing phenotype along with CD8+ infiltration and inflammation in drug-sensitized skin. B7 costimulatory molecule blockade prevented CD8+ T cell activation. These Tg mice provide a model for ABC tolerance and for the generation of HLA-B*57:01–restricted, ABC-reactive CD8+ T cells dependent on both HLA genetic risk and immunoregulatory host factors.
A transgenic mouse model for HLA-B*57:01–linked abacavir drug tolerance and reactivity

Marco Cardone,1 Karla Garcia,1 Mulualem E. Tilahun,2 Lisa F. Boyd,2 Sintayehu Gebreyohannes,1 Masahide Yano,1 Gregory Roderiguez,1 Adovi D. Akue,3 Leslie Juengst,1 Elliot Mattson,1 Suryatheja Ananthula,1 Kannan Natarajan,2Montserrat Puig,1 David H. Margulies,2 and Michael A. Norcross1

1Laboratory of Immunology, Division of Biotechnology Review and Research III (DBRR III), Office of Biotechnology Products (OBP), Office of Pharmaceutical Quality (OPQ), Center for Drug Evaluation and Research (CDER), FDA, Silver Spring, Maryland, USA. 2Laboratory of Immune System Biology, National Institute of Allergy and Infectious Diseases (NIAID), NIH, Bethesda, Maryland, USA. 3Division of Bacterial, Parasitic, and Allergenic Products (DBPAP), Office of Vaccines Research and Review (OVRR), Center for Biologics Evaluation and Research (CBER), US FDA, Silver Spring, Maryland, USA.

Adverse drug reactions (ADRs) are a major obstacle to drug development, and some of these, including hypersensitivity reactions to the HIV reverse transcriptase inhibitor abacavir (ABC), are associated with HLA alleles, particularly HLA-B*57:01. However, not all HLA-B*57:01 patients develop ADRs, suggesting that in addition to the HLA genetic risk, other factors may influence the outcome of the response to the drug. To study HLA-linked ADRs in vivo, we generated HLA-B*57:01–Tg mice and show that, although ABC activated Tg mouse CD8+ T cells in vitro in a HLA-B*57:01–dependent manner, the drug was tolerated in vivo. In immunocompetent Tg animals, ABC induced CD8+ T cells with an anergy-like phenotype that did not lead to ADRs. In contrast, in vivo depletion of CD4+ T cells prior to ABC administration enhanced DC maturation to induce systemic ABC-reactive CD8+ T cells with an effector-like and skin-homing phenotype along with CD8+ infiltration and inflammation in drug-sensitized skin. B7 costimulatory molecule blockade prevented CD8+ T cell activation. These Tg mice provide a model for ABC tolerance and for the generation of HLA-B*57:01–restricted, ABC-reactive CD8+ T cells dependent on both HLA genetic risk and immunoregulatory host factors.

Introduction

Adverse drug reactions (ADRs) have been defined by the World Health Organization (WHO) as noxious and unintended responses to a drug given at a dose established for the prophylaxis, diagnosis, or therapeutic treatment of a disease. ADRs include a group of immune-mediated adverse side effects referred to as drug hypersensitivity reactions (DHRs) or drug allergies. DHRs are often unpredictable (idiiosyncratic) and reveal a broad range of symptoms from mild to severe, occasionally leading to death from drug-induced liver injury (DILI), Stevens-Johnson syndrome (SJS), or toxic epidermal necrolysis (TEN). The systemic inflammatory condition is complex, but drug-reactive T cells play a major role. Such DHRs represent a major obstacle to the success of a therapeutic drug, both during its development and post-market surveillance, as well as a global economic burden for public health. The recognition that certain DHRs are associated with alleles of the HLA class I and/or II molecules (I) provided some insight into the mechanisms of the immunopathogenesis of these reactions. However, many details of the mechanism of DHRs in patients are still unknown.

HLA-B*57:01 has been shown to be linked to several ADRs, initially to hypersensitivity reactions to the HIV reverse transcriptase inhibitor guanosine analog abacavir (ABC) (2, 3), and subsequently to DILI caused by the penicillin β-lactam antibiotic flucloxacillin (4) or the antitumor tyrosine kinase inhibitor pazopanib (5). ABC hypersensitivity reaction (AHR) is a severe multisystem syndrome reported in ABC-treated HIV-infected individuals within 6 weeks of treatment (median time to onset of 8 days). Clinical symptoms can include skin rash, fever, malaise, and gastrointestinal disorders (6). Skin biopsies from AHR rashes and from positive ABC patch tests show a mixture of infiltrating CD8+ and CD4+ T lymphocytes (7), whereas drug-exposed but tolerant patients have negative patch tests. Peripheral blood cells from ABC-hypersensitive individuals rapidly respond to the drug in vitro by releasing high levels of TNF or IFN-γ compared with levels seen in cells from ABC-tolerant subjects (8, 9) and were found to be CD8+ T lymphocytes (8, 10). ABC-responsive CD8+ T cells are also present in drug-naive HLA-B*57:01 donors (10–14). These cells originate from both naïve and memory CD8+ T lymphocytes, do not require the help of CD4+ T cells, and show proliferative capacity and cytokine production when stimulated in vitro.

Of note, AHR has been addressed by the US FDA in the FDA Alert of July 24, 2008 (15), which recommended the screening of patients for HLA-B*57:01 before initiating or resuming treatment with ABC or ABC-containing medications. Nevertheless, the extraordinary specificity of AHR for the HLA risk allele, with 100% of AHR patients being confirmed as HLA-B*57:01 (16, 17), made ABC an excellent candidate for studying the mechanisms responsible for HLA-associated ADRs. Several laborato-
specific conditions may determine the outcome of responses to ABC. The immune system of an HIV-infected individual can be shaped by the virus itself and by secondary effects from infection. HIV, which mainly targets CD4+ T cells, can induce innate and adaptive immune activation and inflammation, which can also persist during antiretroviral treatment (22).

Activation of T cells is controlled by regulatory elements such as immune receptors and Tregs. Inhibitory receptors including PD-1, CTLA-4, LAG3, TIM3, and TIGIT can be coexpressed at different levels and in various combinations by reactive CD8+ T lymphocytes and play a central role in maintaining T cell homeostasis, self-tolerance, and control of immune responses in cancer and chronic viral infections (23, 24). Tregs ensure peripheral immune control and self-reacting CD8+ T cells are a plausible source of regulatory T cells in the context of autoimmunity (25–27).

Figure 1. ABC activates Tg mouse CD8+ T cells in vitro in an HLA-B*57:01-dependent manner. Cultures of purified splenic CD8+ T cells and cultures of total LN cells from drug-naive HLA-B*57:01-Tg (B*57:01) or WT mice. (A) Bright-field microscopy images (original magnification, ×10) of purified CD8+ T cells on day 5 of culture. Data are from 1 of 3 representative experiments. (B) IL-2, IFN-γ, and granzyme B (GZB) in supernatants of purified CD8+ T cells at the indicated time of culture. Data represent the mean ± SEM of ELISA results. Dots indicate the averages of technical replicates in each condition within individual experiments (n = 3–7 experiments). (C and D) Percentage of PD-1+, CD25+, and IFN-γ+ cells within CD8+ (C) and CD4+ (D) T lymphocytes in Tg purified CD8+ T cells and total LN cells cultured for 5 days. Flow cytometric data are from 1 of 2 representative experiments. (E) IFN-γ release by ABC-reactive CD8+ T cells restimulated with 5 μg/ml ABC, in the absence or presence of the specified mAb, following 14 days of primary stimulation. IFN-γ enzyme-linked immunosorbent spot (ELISpot) data show 4 replicates per condition from 1 of 3 representative experiments. *P < 0.05 and **P < 0.005, by unpaired, 2-tailed Student’s t test. None, no drug.
The Journal of Clinical Investigation

RESEARCH ARTICLE

Here, we generated and exploited a Tg mouse model for HLA-B*57:01-restricted ABC tolerance and reactivity. We show that although CD8+ T lymphocytes from drug-naive Tg mice were rapidly activated in vitro by ABC, Tg animals tolerated the drug in vivo. In immunocompetent Tg mice, ABC induced a transient response in lymphoid organs that was characterized by the stimulation of reactive CD8+ T cells displaying an anergy-like phenotype that did not lead to ADR. In contrast, depletion of CD4+ T lymphocytes by suppressing reactive T lymphocytes through various mechanisms such as the maintenance of DCs in an immature state (25). The ability of CD4+ Tregs to affect the optimal costimulation of reactive lymphocytes has been shown to be crucial for preventing autoimmunity. The role of immune receptors, regulatory cells, and costimulation in influencing the outcome of the response to a drug, however, has not yet been addressed in patients or in in vivo animal models of DHR.
cytes induced a break in immune tolerance, possibly by enhancing antigen-presenting cell (APC) costimulation, leading to a T cell effector state necessary for the development of ADR.

Results

**CD8+ T cells from drug-naive HLA-B*57:01–Tg mice are activated by ABC in vitro.** To study the mechanisms behind the development of HLA-B*57:01-linked ADRs in vivo, we generated a Tg mouse expressing a chimeric HLA-B*57:01 molecule under the control of the promoter of the mouse MHC class I gene, H2-K^d^ (see Methods). The chimeric protein contains the human α1 and α2 domains of the risk allele HLA-B*57:01 and the mouse α3 domain of the MHC class I, H2-D^d^. The H2-D^d^α3 was inserted to facilitate the interaction of the HLA-B*57:01 with the mouse coreceptor CD8 (ref. 26 and our unpublished observations, and Supplemental Figure 1A; supplemental material available online with this article; https://doi.org/10.1172/JCI99321DS1). We verified the expression of HLA-B*57:01 as well as the H2-D^d^α3 subunit by flow cytometry in lymphoid organs and cells, including CD4+ T cells, CD8+ T cells, and B220+CD19+ B cells from the blood of Tg and WT mice (Supplemental Figure 1B and Supplemental Figure 2).

We first evaluated the responsiveness of HLA-B*57:01–Tg mice to ABC in vitro by monitoring morphological changes, secretion of effector molecules, and expression of cell-surface activation markers in drug-exposed T lymphocytes (Figure 1). Splenic CD8+ T cells from drug-naive Tg animals were left untreated or stimulated with ABC for 5 days in the presence of ABC-pulsed irradiated Tg splenocytes. In some experiments, T cells were then expanded for up to 3 days, induced a break in immune tolerance, possibly by enhancing antigen-presenting cell (APC) costimulation, leading to a T cell effector state necessary for the development of ADR.

Results

**CD8+ T cells from drug-naive HLA-B*57:01–Tg mice are activated by ABC in vitro.** To study the mechanisms behind the development of HLA-B*57:01-linked ADRs in vivo, we generated a Tg mouse expressing a chimeric HLA-B*57:01 molecule under the control of the promoter of the mouse MHC class I gene, H2-K^d^ (see Methods). The chimeric protein contains the human α1 and α2 domains of the risk allele HLA-B*57:01 and the mouse α3 domain of the MHC class I, H2-D^d^. The H2-D^d^α3 was inserted to facilitate the interaction of the HLA-B*57:01 with the mouse coreceptor CD8 (ref. 26 and our unpublished observations, and Supplemental Figure 1A; supplemental material available online with this article; https://doi.org/10.1172/JCI99321DS1). We verified the expression of HLA-B*57:01 as well as the H2-D^d^α3 subunit by flow cytometry in lymphoid organs and cells, including CD4+ T cells, CD8+ T cells, and B220+CD19+ B cells from the blood of Tg and WT mice (Supplemental Figure 1B and Supplemental Figure 2).

We first evaluated the responsiveness of HLA-B*57:01–Tg mice to ABC in vitro by monitoring morphological changes, secretion of effector molecules, and expression of cell-surface activation markers in drug-exposed T lymphocytes (Figure 1). Splenic CD8+ T cells from drug-naive Tg animals were left untreated or stimulated with ABC for 5 days in the presence of ABC-pulsed irradiated Tg splenocytes. In some experiments, T cells were then expanded for up to 3 days.

**Figure 3. Transcriptional framework of sorted CD8+ T cells from treated HLA-B*57:01–Tg mice.** Gene expression analysis of CD8+ T cells sorted from LNs of treated Tg animals. (A) Heatmap shows Z-score–transformed expression values of genes selected as specified in the Methods. Data from individual mice within each group of 5 independent experiments were collapsed prior to gene clustering. (B) Venn diagrams show the number of genes within the leading edge of the gene signatures of the GSEA in Supplemental Figure 6. Genes were counted once, independently of their appearance in multiple signatures. Empty areas indicate an absence of genes. (C and D) Representative gene clusters from the heatmap in A. Listed genes are those significantly upregulated (P < 0.05), with a fold-change of 1.5 or greater and with normalized RNA counts above the geometric mean ± 3 SD of the negative controls, in at least 1 treatment group as compared with vehicle (veh) (see also Supplemental Tables 1–3).
events leading to AHR, we next tested the effects of ABC exposure in vivo. We injected ABC i.p. and applied it topically on the ears of Tg mice for up to 4 weeks (Supplemental Figure 3A), simulating a time frame within which drug-allergic patients report adverse reactions (6). We found that ABC-treated Tg animals showed no signs of skin hypersensitivity. Scarring or dermal/epidermal infiltration by CD8+ T cells was not observed in the drug- or vehicle-exposed mice after a 3-week treatment period (Figure 2A and Supplemental Figure 4). These results raised the question of the potential role of immunosuppressive mechanisms driven by coinhibitory molecules and/or immunosuppressive cells in preventing AHR.

Therefore, we measured the expression of coinhibitory receptors on CD8+ T cells from LNs of ABC-exposed Tg mice throughout the 10 days of drug administration. With the exception of PD-1 and IL-2Ra subunit (CD25) than did the cells left untreated. Moreover, approximately 20% of PD-1' and CD25' drug-responsive T cells produced IFN-γ (Figure 1C). CD4' T lymphocytes, unlike CD8' lymphocytes, did not show the same activation phenotype (Figure 1D), suggesting that ABC-induced immune responses in HLA-B*57:01-Tg mice are mediated by drug-reactive CD8' T cells, consistent with findings reported in both HLA-B*57:01' ABC-hypersensitive patients and normal donors (8, 10–14). Next, we verified that the response to ABC in Tg animals was CD8 and HLA-B*57:01 dependent by using neutralizing Abs against mouse CD8 (anti-CD8) or HLA B/C (anti–HLA B/C) (Figure 1E). Release of IFN-γ was observed only in cultures of drug-responsive CD8' T cells restimulated with ABC and was inhibited in the presence of anti-CD8- or anti–HLA B/C-neutralizing Abs.

Overall, these results demonstrated that the spleens and LNs of drug-naive HLA-B*57:01-Tg mice contained drug-reactive CD8' T lymphocytes with effector potential that could rapidly respond to ABC stimulation in vitro. In addition, expanded drug-reactive CD8' T cells could rapidly respond to ABC stimulation in a HLA-B*57:01-dependent manner.

**HLA-B*57:01-Tg mice tolerate ABC in vivo.** Motivated by the results obtained in vitro, and with the aim of dissecting the immune

14 days with IL-2. CD8' T cell cultures from drug-naive WT mice were used as controls. ABC-treated cells from Tg, but not WT, animals acquired the morphology of activated T lymphocytes and released low but significant levels of IL-2 (by day 2) as well as large amounts of IFN-γ and granzyme B within 5 days of exposure to the drug (Figure 1, A and B). ABC-reactive CD8' T cells were generated from both purified splenic CD8' T lymphocytes and pooled lymph node (LN) cells. These cells expressed higher levels of activation markers (PD-1 and IL-2Ra subunit [CD25]) than did the cells left untreated. Moreover, approximately 20% of PD-1' and CD25' drug-responsive T cells produced IFN-γ (Figure 1C). CD4' T lymphocytes, unlike CD8' lymphocytes, did not show the same activation phenotype (Figure 1D), suggesting that ABC-induced immune responses in HLA-B*57:01-Tg mice are mediated by drug-reactive CD8' T cells, consistent with findings reported in both HLA-B*57:01' ABC-hypersensitive patients and normal donors (8, 10–14). Next, we verified that the response to ABC in Tg animals was CD8 and HLA-B*57:01 dependent by using neutralizing Abs against mouse CD8 (anti-CD8) or HLA B/C (anti–HLA B/C) (Figure 1E). Release of IFN-γ was observed only in cultures of drug-responsive CD8' T cells restimulated with ABC and was inhibited in the presence of anti-CD8- or anti–HLA B/C-neutralizing Abs.

Overall, these results demonstrated that the spleens and LNs of drug-naive HLA-B*57:01-Tg mice contained drug-reactive CD8' T lymphocytes with effector potential that could rapidly respond to ABC stimulation in vitro. In addition, expanded drug-reactive CD8' T cells could rapidly respond to ABC stimulation in a HLA-B*57:01-dependent manner.

**HLA-B*57:01-Tg mice tolerate ABC in vivo.** Motivated by the results obtained in vitro, and with the aim of dissecting the immune
reaching basal levels by day 10 (Figure 2B). ABC-experienced CD8+ T lymphocytes released similar or greater amounts of IFN-γ compared with drug-naive CD8+ T cells after in vitro restimulation with ABC, but only when isolated from the LNs of Tg animals treated with the drug for 4 to 5 days (Figure 2E). These data suggested that, in vivo, ABC-reactive CD8+ T cells rapidly became unresponsive or were deleted. To determine whether PD-1 restrained drug-reactive cells, HLA-B*57:01–Tg mice were exposed to ABC in the presence of a neutralizing anti–PD-1 mAb. Anti–PD-1 mAb treatment neither significantly increased the percentage of CD8+ T lymphocytes expressing KLRG1 and CLA (Supplemental Figure 5), nor predisposed ABC-treated animals to develop skin hypersensitivity (data not shown). Taken together, these results indicated that the ABC-induced adverse immune response in vivo was controlled by immunosuppressive mechanisms. This resulted from a systemic induction of reactive CD8+ T cells that first entered an early activation phase, which was then arrested before progressing to tissue damage. The failure of PD-1 neutralization to predispose drug-treated Tg mice to ADR and the lack of coexpression of PD-1 with other inhibitory molecules on ABC-responsive CD8+ T cells suggested that this control was exerted by cell-extrinsic mechanisms provided by immunosuppressive cells rather than cell-intrinsic mechanisms dependent on the expression of inhibitory receptors.

CD4+ T cell depletion predisposes Tg mice to ABC reactivity in vivo. Patients at risk of developing AHR after exposure to ABC are HLA-B*57:01+ HIV-infected individuals who may have an altered immune system shaped by a variety of factors including the virus. Given this and considering that HIV targets CD4+ T cells and that ABC-reactive CD8+ T lymphocytes do not require CD4+ help to become activated, we explored whether CD4 depletion could alter the immune status of Tg animals, predisposing them to ADR. Although human studies do not show a correlation between CD4+ counts and susceptibility to developing AHR (16), the mouse model affords an opportunity to directly examine the potential role of CD4 depletion in CD8+ T cell activation by ABC. Therefore, we administered a depleting anti–mouse CD4 mAb (anti-CD4) to HLA-B*57:01–Tg mice periodically as outlined in Supplemental Figure 3B. Tg animals treated with ABC alone as well as ABC-stimulated, CD4-depleted (anti-CD4 + ABC) WT mice were used as controls. By week 3, the Tg mice treated with anti-CD4 plus ABC (anti-CD4 + ABC) showed robust signs of skin hypersensitivity on the treated ears, unlike the animals that were not CD4 depleted (Figure 2, A and F). The skin reaction was characterized by scarring, abundant dermal and epidermal infiltration of CD8+ T cells by IHC, and increased ear thickness (Figure 2, F and G, and Supplemental Figure 4). We did not observe skin hypersensitivity in anti-CD4 plus ABC WT mice and observed minimal skin hypersensitivity in the Tg animals that received anti-CD4 and vehicle instead of the drug (anti-CD4 + vehicle). We also found that by day 10, the LNs of anti-CD4 plus ABC Tg mice had a higher percentage of CD8+PD-1+ T cells than did the ABC or anti-CD4 plus vehicle Tg animals (Figure 2H), suggesting an ongoing systemic reaction. These data implicated CD4+ T lymphocytes in the maintenance of immune tolerance during treatment of the Tg mice with ABC and in the prevention of ADRs, despite the presence of the genetic risk factor HLA-B*57:01. CD4 depletion promotes the development of ABC-reactive CD8+ T cells with an effector-like, skin-homing phenotype. Both control and CD4-depleted HLA-B*57:01–Tg mice responded to ABC with a marked accumulation of reactive CD8+PD-1+ T cells in the LNs. Expression of PD-1, a marker of both effector and dysfunctional T lymphocytes (23, 24), was insufficient to explain the apparent differences in the activation status of ABC-responsive CD8+ T cells and the clinical outcome of Tg animals in each treatment arm.
Thus, to characterize better ABC-reactive cells, we performed a comparative gene expression analysis of sorted CD3+CD4+CD8+ T lymphocytes from LNs of nondepleted or CD4-depleted Tg mice treated with the drug. We focused on days 3 and 4 of ABC exposure to identify the transcriptional phenotype of early activated CD8+ T cells and on day 10 to reveal the characteristics of persistent drug-reactive CD8+ T lymphocytes in anti-CD4 plus ABC Tg mice that eventually developed skin hypersensitivity. We evaluated the expression of 591 genes related to immune function, lymphocyte dysfunction, and/or effector responses, and we compared the resulting gene expression profiles with previously described gene signatures to identify associations with T cell anergy (27), exhaustion (28), effector function (28, 30, 31) (Figure 3B, and Supplemental Table 1). By day 10, however, ABC-CD8+ T cells showed traits of CD8+ T lymphocytes from vehicle-treated Tg mice (vehicle-CD8+ T cells) (Figure 3A), thus confirming the transient activation of drug-reactive T cells in immunocompetent Tg mice and suggesting a possible cause for the lack of development of ADR.

CD8+ T cells from anti-CD4 plus ABC Tg mice (anti-CD4 + ABC-CD8+ T cells) showed a transcriptional phenotype markedly distinct from that of ABC-CD8+ T cells (Figure 3A). Although both types of cells shared expression of several genes related to T cell anergy, the transcriptional profile of anti-CD4 plus ABC-CD8+ T cells was particularly enriched for genes that define signatures of effector and exhausted CD8+ T cells in models of acute and chronic viral infections (28, 30, and 31) (Figure 3B, and Supplemental Figure 6). Genes unique to the effector signature included Gzma, Ccr2, I12rb2, I18r1, I18rap, Krlc1, Casp1, Igtax, and Igh1, whereas those associated with both effector and exhaustion signatures included the inhibitory receptors Pdcd1, Lag3, and Ctla4 as well as Jak3, Lag3, and Cd40lg (Supplemental Figure 6), but also: (a) transcription factors including the immunosuppressive transcriptional regulator Egr3 (27, 33); (b) signaling molecules including the marker of T cell dysfunction Dgkz (34); and (c) cytokines and receptors (e.g., Lta, Tnf, Tnfsf8, Tnfsf1b, Tgfrb2) (Figure 3C and Supplemental Table 1). By day 10, however, ABC-CD8+ T cells showed traits of CD8+ T lymphocytes from vehicle-treated Tg mice (vehicle-CD8+ T cells) (Figure 3A), thus confirming the transient activation of drug-reactive T cells in immunocompetent Tg mice and suggesting a possible cause for the lack of development of ADR.

CD8+ T cells from anti-CD4 plus ABC Tg mice (anti-CD4 + ABC-CD8+ T cells) showed a transcriptional phenotype markedly distinct from that of ABC-CD8+ T cells (Figure 3A). Although both types of cells shared expression of several genes related to T cell anergy, the transcriptional profile of anti-CD4 plus ABC-CD8+ T cells was particularly enriched for genes that define signatures of effector and exhausted CD8+ T cells in models of acute and chronic viral infections (28, 30, and 31) (Figure 3B, and Supplemental Figure 6). Genes unique to the effector signature included Gzma, Ccr2, I12rb2, I18r1, I18rap, Krlc1, Casp1, Igtax, and Igh1, whereas those associated with both effector and exhaustion signatures included the inhibitory receptors Pdcd1, Lag3, and Ctla4 as well as Jak3, Lag3, and Cd40lg (Supplemental Figure 6), but also: (a) transcription factors including the immunosuppressive transcriptional regulator Egr3 (27, 33); (b) signaling molecules including the marker of T cell dysfunction Dgkz (34); and (c) cytokines and receptors (e.g., Lta, Tnf, Tnfsf8, Tnfsf1b, Tgfrb2) (Figure 3C and Supplemental Table 1). By day 10, however, ABC-CD8+ T cells showed traits of CD8+ T lymphocytes from vehicle-treated Tg mice (vehicle-CD8+ T cells) (Figure 3A), thus confirming the transient activation of drug-reactive T cells in immunocompetent Tg mice and suggesting a possible cause for the lack of development of ADR.
potential of these cells to cause the in vivo outcome observed in mice of this group.

We next performed flow cytometric analysis on cells from LN, spleen, and blood to confirm the protein expression levels of several of the genes identified in the transcriptional signatures and/or to examine the state of activation of the CD8+ T cells later during disease. By day 10 of drug administration, CD8+ T lymphocytes in the LNs of only the anti-CD4 plus ABC Tg animals were highly enriched for cells coexpressing the inhibitory receptors PD-1 and LAG3 and TIM3 or CTLA-4 (likely representing T cells in a more active functional state) (Figure 4, A and B). CD25+ and/or KLRG1+CD8+ T cells were found in LNs, spleen, and blood of anti-CD4 plus ABC Tg mice, even at 3 week of drug exposure (Figure 4C), when animals manifested skin hypersensitivity on the treated ears. At the same time, a significant proportion of splenic anti-CD4 plus ABC-CD8+ T cells also expressed the costimulatory receptor 4-1BB (Figure 4D) as well as Ifng and Gzmb (data not shown) when restimulated in vitro with drug, unlike cells from animals of the other treatment groups. In addition, LNs and blood from anti-CD4 plus ABC Tg, but not WT, mice revealed an increased percentage of CD8+ T cells expressing the skin-homing molecules CLA and CXCR3 (Figure 5A). These results indicate that in anti-CD4 plus ABC Tg animals, activated ABC-responsive CD8+ T lymphocytes have the potential to target the skin, despite showing some dysfunctional traits, and can still be detected in the circulation by week 3 of treatment. Consistently, by week 3, skin biopsies from anti-CD4 plus ABC Tg animals showed remarkable inflammation characterized by infiltrating effector CD8+ T cells (Figure 2F and Supplemental Figure 4) and macrophages (data not shown) and elevated expression of genes encoding effector markers, cytotoxic factors, inflammatory chemokines, and adhesion molecules (Figure 5B). Thus, CD4 depletion, although promoting T cell dysfunction when administered alone, conditioned the immune system of Tg mice toward becoming more permissive for ABC to induce ADRs.

CD4 depletion boosts the DC maturation required for induction of skin-homing, ABC-reactive CD8+ T cells in vivo. Enrichment in anti-CD4 plus ABC-CD8+ T cells of gene sets characteristic of effector T cells from viral infection models in which costimulatory and inflammatory conditions were optimal led us to hypothesize possible mechanisms by which the lack of CD4+ T cells could overcome tolerance. CD4+ Tregs can control autoimmunity as well as graft-versus-host disease by restraining DC maturation (35–38). Therefore, we explored whether a similar mechanism of action could be in place in our model by characterizing the maturation profile of DCs from the treated Tg mice. We analyzed the expression of the costimulatory molecules CD86, CD80, and CD40, the coinhibitory receptor PD-L1, and HLA-B*57:01 on total CD11c+MHC-II+ DCs and the subset of XCR1+ DCs from LNs (Figure 6A and Supplemental Figure 7, A and B). Notably, DCs with higher levels of CD80 and CD86 expression, particularly those from anti-CD4 plus ABC Tg animals, also showed greater expression of PD-L1 (Figure 6B). CD80 has been demonstrated by others to prevent the inhibitory interaction of PD-L1–PD-1 by binding to PD-L1, while also costimulating via CD28 on T lymphocytes (39–41). Similarly, the high levels of CD80 expression on DCs from anti-CD4 plus ABC Tg mice may lead to an effective costimulatory phenotype, overcoming the PD-L1–inhibitory effect.

To test the impact of costimulation on the development of drug-responsive CD8+ T cells in vivo, ABC Tg animals and anti-
The discovery of genetic associations between certain ADR and HLA alleles led to the examination of immune mechanisms underlying the manifestation of HLA-restricted drug-allergies. These efforts resulted in several studies that shed light on models of HLA-drug–peptide–TCR interaction and on the nature of drug-reactive T cell responses (1, 42). Of note, earlier studies were performed in vitro and failed to explain why some patients carrying a known HLA risk allele tolerate the culprit drug, highlighting the complexity of the immunopathogenesis of HLA-linked ADRs in the living organism (13, 16, 17). Here, we used an HLA-B*57:01–Tg mouse and reveal: (a) the nature of the systemic but defective response to ABC in drug-tolerant Tg animals, which may explain ABC tolerance in 45% of HIV-infected HLA-B*57:01+ individuals, and (b) the need for optimal costimulation for ABC to induce drug-reactive effector CD8+ T cells with potential to cause skin hypersensitivity in Tg mice.

Using an approach similar to that described by others in human studies using cultures of peripheral blood mononuclear cells (PBMCs) from ABC-naive, HLA-B*57:01+ healthy, normal donors (10, 11, 13, 14), we demonstrated here that splenic and LN cells from ABC-naive HLA-B*57:01–Tg mice gave rise to functionally active, drug-responsive CD8+ but not CD4+ T cells when cultured in vitro with the drug. Consistent with the findings in humans, in vitro stimulation of mouse CD8+ T cells by ABC required expression of the risk allele HLA-B*57:01. However, compared with the response observed in PBMCs from ABC-naive, HLA-B*57:01+ healthy, normal donors, Tg CD8+ T cells in our study reacted more rapidly to ABC and became activated within 5 days of stimulation with the drug.

To address this, we explored the level of DC maturation in LN cells from drug-naive mice ex vivo and in culture. Surprisingly, DC maturation, characterized by upregulation of the B7 costimulatory molecules CD86 and CD80, occurred as a consequence of cell culture, even in the absence of ABC (Figure 8A and Supplemental Figure 8). Addition of CTLA-4–Ig or anti-CD80 mAb to cultures impaired the production of IFN-γ by LN cells treated with ABC (Figure 8B).

Taken together, these results indicated that APC-dependent costimulation was needed for ABC to activate CD8+ T lymphocytes. In vivo, unlike in vitro, DC maturation was boosted by the lack of CD4+ T cells, which was required to develop drug-reactive effector CD8+ T cells with pathogenic potential in this mouse model of HLA-B*57:01–linked ABC drug reactivity.

### Discussion

The discovery of genetic associations between certain ADR and HLA alleles led to the examination of immune mechanisms underlying the manifestation of HLA-restricted drug-allergies. These efforts resulted in several studies that shed light on models of HLA-drug–peptide–TCR interaction and on the nature of drug-reactive T cell responses (1, 42). Of note, earlier studies were performed in vitro and failed to explain why some patients carrying a known HLA risk allele tolerate the culprit drug, highlighting the complexity of the immunopathogenesis of HLA-linked ADRs in the living organism (13, 16, 17). Here, we used an HLA-B*57:01–Tg mouse and reveal: (a) the nature of the systemic but defective response to ABC in drug-tolerant Tg animals, which may explain ABC tolerance in 45% of HIV-infected HLA-B*57:01+ individuals, and (b) the need for optimal costimulation for ABC to induce drug-reactive effector CD8+ T cells with potential to cause skin hypersensitivity in Tg mice.

Using an approach similar to that described by others in human studies using cultures of peripheral blood mononuclear cells (PBMCs) from ABC-naive, HLA-B*57:01+ healthy, normal donors (10, 11, 13, 14), we demonstrated here that splenic and LN cells from ABC-naive HLA-B*57:01–Tg mice gave rise to functionally active, drug-responsive CD8+, but not CD4+, T cells when cultured in vitro with the drug. Consistent with the findings in humans, in vitro stimulation of mouse CD8+ T cells by ABC required expression of the risk allele HLA-B*57:01. However, compared with the response observed in PBMCs from ABC-naive, HLA-B*57:01+ healthy, normal donors, Tg CD8+ T cells in our study reacted more rapidly to ABC and became activated within 5 days of stimulation with the drug.

We next tested the effects of ABC exposure in vivo, expecting that a fraction of the HLA-B*57:01–Tg mice would develop adverse reactions after drug administration, given the studies in...
humans (16, 17). However, unlike HIV-infected patients, Tg animals tolerated ABC without showing signs of AHR. Nevertheless, we noticed an accumulation of drug-reactive CD8\(^+\) T cells expressing PD-1 in the LNs of the treated mice. These lymphocytes originated predominantly from CD44\(^+\)CD62L\(^+\) memory-like cells, suggesting that even in Tg animals, preexisting memory CD8\(^+\) T cells, directed against either self or foreign antigens, could be a source of drug-responsive T lymphocytes, as was similarly proposed in humans (13, 14). Of note, “innate” memory T cells recognizing self-peptide–MHC ligands exist even in germ-free animals and in mice housed under pathogen-free conditions (43). Further studies on memory cells identified in our model will be required to further characterize the ABC-specific response.

In vivo, reactive PD-1\(^+\) T cells proliferated and lost the naive/memory marker CD62L within 4 days of treatment, showing their potential to enter an early activation phase. However, PD-1\(^+\) T cells were only transiently detectable and returned to basal levels by day 10. These ABC-CD8\(^+\) T cells shared anergic traits previously associated with T cells stimulated in the absence of costimulation (27). Of note was the expression of the zinc finger transcription factor gene Egr3, which, together with Egr2, has been shown to prevent autoimmunity (44) by driving a negative genetic program responsible for dampening effector differentiation and promoting T cell anergy (27, 33), while ensuring a certain level of proliferation (33). ABC-CD8\(^+\) T cells also expressed PD-1 and its transcriptional regulator Nfatc1 (32). PD-1, which is rapidly upregulated upon activation, may be expressed on functionally active memory T lymphocytes (45), short-lived effectors, and especially on dysfunctional T cells (24) including anergic ones (46, 47). In the latter, PD-1 upregulation has been shown to promote anergy during tolerogenic stimulation in LNs (46), an action that could be mediated by suppressing IL-2 production of reactive T cells (47). In addition, interference with PD-1–PD-L1 interaction was proven to reverse this process (46). Thus, we explored whether blockade of PD-1 could prevent ABC-CD8\(^+\) T cell dysfunction in the LNs of treated Tg mice, making them susceptible to develop drug reactivity. However, anti-PD-1 neither helped ABC-CD8\(^+\) T cells to progress toward a functionally active state with skin-homing potential, nor predisposed ABC-treated Tg mice to develop ADRs. Overall, these results provided a model for ABC tolerance and highlight the finding that the exposure to a broad range of neoantigens caused by ABC treatment is not sufficient to induce AHR, despite the presence of the HLA genetic risk.

CD4\(^+\) Tregs have been shown to maintain immunological tolerance (48) and ensure memory CD8\(^+\) T cell quiescence under homeostatic conditions (49), a process that could also affect ABC-responsive, preexisting memory T lymphocytes in Tg mice. In addition, as seen in human studies, we show here that ABC-reactive Tg CD8\(^+\) T cells do not require CD4\(^+\) help to become activated. Therefore, we depleted CD4\(^+\) T cells prior to ABC administration to explore whether this immune alteration could predispose HLA-B*57:01–Tg mice to develop ADRs. Similar to what was observed in AHR patients (7), skin from the treated ears of anti-CD4 plus ABC Tg animals showed signs of cutaneous reaction characterized by remarkable inflammation and the presence of infiltrating cytotoxic CD8\(^+\) T cells. The skin was also infiltrated by macrophages that were possibly recruited by locally produced chemokines such as CCL5. The anti-CD4 plus ABC treatment, however, did not allow the assessment of skin infiltration by CD4\(^+\) T cells, as seen in skin biopsies from ABC-hypersensitive patients (7), because of the depletion of these cells. Although systemic CD8\(^+\) T cell activation occurred in LNs, spleen, and blood, other clinical symptoms related to AHR observed in HIV\(^+\) individuals (6), such as increased body temperature (data not shown) or lethargy, were not observed. Thus, anti-CD4 plus ABC Tg mice cannot be considered an exact model for human AHR, but rather a model for generating HLA-B*57:01-linked ABC-reactive CD8\(^+\) T cells with pathogenic potential. Indeed, though mouse models are critical for the objective evaluation of both genetic and environmental factors in terms of their contribution to disease etiology, many aspects of human biology cannot be accurately assessed in such models. Data from multiple study approaches — animal and human, in vivo and in vitro, experimental and observational — must be integrated to develop an accurate mechanistic understanding.

Unlike ABC-CD8\(^+\) T cells, CD8\(^+\) T lymphocytes from anti-CD4 plus ABC Tg mice displayed gene expression patterns similar to those reported for effector T cells in acute viral infection models (28, 30, 31), in which adaptive immune responses arise under optimal costimulatory conditions. Nevertheless, anti-CD4 plus ABC-CD8\(^+\) T cells also showed molecular traits found in dysfunctional lymphocytes (27–29), particularly in exhausted cells, indicating the coexistence of reactive CD8\(^+\) T cells at different activation states in Tg mice treated with anti-CD4 and ABC. Since anti-CD4 plus vehicle–CD8\(^+\) T cells showed predominantly markers of dysfunction, we thus concluded that the presence of dysfunctional CD8\(^+\) T cells in anti-CD4 plus ABC Tg animals was mainly due to the effect of CD4 depletion, as has been described in infection and vaccination models (23, 50). Moreover, selective depletion and/or impaired functionality of Tregs have been shown to lead to autoimmunity (37, 51, 52). Instead, in our Tg mice, the loss of CD4\(^+\) T cells alone, which included CD4\(^+\) Tregs, had mild effects, and the presence of ABC was necessary for the development of pathogenic drug-reactive CD8\(^+\) T cells and skin hypersensitivity.

The strikingly different gene expression phenotypes of ABC-CD8\(^+\) and anti-CD4 plus ABC-CD8\(^+\) T cells along with the well-known role of CD4\(^+\) Tregs in preventing DC maturation (35–38, 53, 54) made us question whether loss of CD4\(^+\) T lymphocytes overcame the immune tolerance to ABC and predisposed HLA-B*57:01–Tg mice to develop ABC drug reactivity by enhancing DC maturation. Indeed, we found that treatment with anti-CD4 mAb alone, and even more so in the presence of the drug, upregulated the expression of costimulatory molecules on total lymphoid CD11c\(^+\)MHC-II\(^+\) DCs that were required in Tg animals exposed to ABC for the differentiation of drug-reactive CD8\(^+\) T cells with potential to target the skin.

During viral infection, CD4\(^+\) T lymphocytes have been shown to provide help priming CD8\(^+\) T cells when colocalized with them on XCR1\(^+\) DCs in LNs (55, 56). However, several reports (13, 14) demonstrated that CD4\(^+\) T cell help is not required for expanding ABC-reactive CD8\(^+\) T lymphocytes in cultures of memory or naive cells from HLA-B*57:01\(^+\) donors, and our results with Tg mice supported this finding. We also found that in vivo CD4\(^+\) T cells can prevent adverse immune responses to ABC by keeping the state of DC activation under control. Therefore, we hypothesize that in
ABC Tg animals, XCR1+ DCs can provide drug-responsive CD8+ T lymphocytes with tolerogenic stimulation when CD4+ Tregs are present in the co-cluster or allow an optimal costimulation when Tregs are absent. Indeed, we observed a remarkable increase in expression of CD80 and HLA-B*57:01 molecules on XCR1+ DCs in the LNs of ABC Tg mice after CD4+ T cell depletion. This suggested that XCR1+ DCs could help determine the fate of drug-responsive CD8+ T cells in vivo and, eventually, the outcome of the response to ABC — tolerogenic or adverse — depending on the presence or absence of CD4+ Tregs in the immediate vicinity. Additional experiments are needed to definitively address the role of Tregs and CD4+ T cells.

Our study highlights the importance of DC-mediated costimulation in influencing the outcome of the response to ABC. Costimulation by professional APCs has been widely recognized as an essential process in providing signal 2 in addition to TCR binding for the activation of both naive and memory T cells (57). However, Adam et al. (13) reported that the intervention of the innate immune system, in particular of professional APCs, is not necessary to trigger T cell responses to ABC in vitro. This conclusion was drawn on the basis of results showing that: (a) ABC does not directly activate in vitro–generated DCs from HLA-B*57:01–individuals to upregulate costimulatory molecules or release inflammatory cytokines (IL-1β, IL-6, TNF); and (b) ABC reactivity can be detected after drug rechallenge in cultures of pure HLA-B*57:01– T cells that were previously expanded in the absence of APCs. Consistent with these reports, we show here that even in Tg mice, ABC alone does not directly activate DCs, either in vivo or in overnight cultures of LN cells. However, beyond the effects of ABC on DC activation and as previously reported by others (58, 59), we also found that DCs from Tg mice spontaneously matured in vitro, regardless of the presence of the drug, and upregulated B7 costimulatory molecules that support the in vitro differentiation of functionally active ABC-responsive CD8+ T cells, as shown in vivo. Thus, our findings, along with a recent report (60) demonstrating that ABC activates the NLRP3 inflammasome for IL-1β release in pathogen-associated molecular pattern–primed (PAMP-primed) human monocytes, reinforce the potential role of the innate immune system, particularly of APCs, in contributing to ABC drug reactivity. Furthermore, the different requirements for DC maturation in vivo and in vitro, as evidenced by our study, might explain differences in the frequency of ABC-induced immune responses in patients in vivo and in culture.

A role of CD4+ Tregs, costimulatory molecules, and/or coinhibitory receptors in the context of drug allergies has been previously suggested in: (a) a mouse model of dinitrofluorobenzene-induced (DNFB-induced) contact hypersensitivity (61); (b) CD4-deficient mice treated with fluocoxacinil to model DILI (62); and (c) human cell cultures exposed to fluocoxacinil or nitroso sulfamethoxazole (SMX-NO) (63, 64). Our study explores the effects of the above-mentioned immunoregulatory players in the context of ABC drug reactivity, especially in vivo, and using a Tg mouse carrying the associated risk allele HLA-B*57:01.

Of note, the complete depletion of CD4+ T cells achieved in our Tg model for ABC drug reactivity is more pronounced than that seen in HIV patients in clinical practice. However, it is well accepted that gut-homing, HIV-specific CD4+ T cells are severely depleted in the intestinal mucosa and show only partial recovery under combination antiretroviral therapy (65). Since this alteration is also associated with microbial translocation (leaking gut), persistent inflammation, and innate and adaptive immune activation, it is possible that anti-CD4–treated Tg mice may also experience similar effects and therefore be more susceptible to ABC exposure, a hypothesis that needs further investigation.

Recently, Susukida et al. (66) reported T cell responses to ABC in a HLA-B*57:01–Tg mouse that coexpressed human B2M, within 1 week of drug administration. Consistent with our results, the authors measured a rapid increase in CD44+CD62L+ CD8+ T cells in LNs and spleen in vivo when ABC was administered orally. Lymphocyte infiltration was observed in skin after ear painting with ABC for 3 days. In contrast, we noted that ABC administration did not directly lead to skin inflammation or scarring and that systemic activation of CD8+ T cells resulted in tolerance within 10 days of drug administration. Susukida et al. did not address the evolution of the early response to ABC in their model, nor did their animals show any clinical effects. Another recently published report from this group described transient alanine aminotransferase (ALT) elevation and liver inflammation 5 days after treatment of mice with CpG-ODN, a TLR-9 agonist, together with ABC (67). We did not observe liver inflammation by histology in our Tg mice, even when animals were depleted of CD4+ T cells and showed robust drug-induced activation of effector CD8+ T cells.

In conclusion, we exploited a Tg animal model for HLA-B*57:01–linked ADR focused on ABC tolerance and the generation of drug-reactive CD8+ T cells with pathogenic potential. This HLA-B*57:01–Tg mouse allows the simultaneous in vivo modeling of the susceptibility conferred by HLA genetic risk and immune regulatory factors that can mitigate pathology. Although AHR in patients may not correlate with CD4 counts (16), depletion of CD4+ in HLA-B*57:01–Tg mice revealed that optimal DC-mediated costimulation predisposed the mice to a break in immune tolerance in the presence of ABC. Nevertheless, since anti-CD4 plus ABC Tg animals did not manifest the full spectrum of clinical symptoms seen in AHR patients, other factors required for AHR development remain to be disclosed. In addition, since HLA-B*57:01 is also associated with DILI caused by fluocoxacinil or pazzopanib, we expect that these Tg mice can help us to better understand the immunopathogenesis of these reactions. Given the unique ability of ABC to activate CD8+ T cells in the absence of CD4+ T cells, additional host factor variables may need to be explored to explain adverse reactions to other drugs. Finally, our work suggests that HLA Tg animals may be used for in-depth characterization of other HLA-linked ADRs.

**Methods**

**Mice.** The HLA-B*57:01/H2-D1 full-length chimeric construct was generated from a full-length HLA-B*57:01 cDNA. The sequences encoding the HLA-B*57:01 a1 and a2 domains were joined to the α3, transmembrane (TM), and cytoplasmic (CY) domains from a cDNA of H2-D1 and subcloned into the vector containing an H2-Kk promoter, 3′ splice, and Ig enhancer designed for transgenic expression (68), as described in greater detail elsewhere (our unpublished observations). HLA-B*57:01–Tg mice were generated by microinjection of C57BL/6 embryos at the
National Cancer Institute transgenic mouse facility using standard methods (69). Founders, identified by Southern blotting, were then followed by flow cytometry on peripheral blood leukocytes with mAb B1.23.2 (70). The animals used in these studies are designated Ch/L-2 (our unpublished observations) and are heterozygous for the transgene on the C57BL/6 background. The genotype of animals was verified by flow cytometry as detailed in the Methods section.

In vitro culture assays. In vitro T cell responses to ABC were measured in cultures of purified CD8+ T lymphocytes and single-cell suspensions from spleens or pooled LNs of WT and/or HLA-B*57:01-Tg mice. Enrichment of ABC-reactive CD8+ T lymphocytes was achieved by adding 10 μg/ml ABC (Ziagen tablets, GlaxoSmithKline) to the cultures on day 0. Purified CD8+ T lymphocytes were cocultured on day 0 with irradiated (30 Gy) splenocytes at a 1:2 CD8+ T cell to feeder ratio. For ELISpot experiments, ABC-reactive CD8+ T cells were first generated by culturing purified CD8+ T lymphocytes and irradiated feeders with 5 μg/ml ABC for 5 days and subsequently expanded in the presence of rhIL2 for up to 14 days. IFN-γ secretion was evaluated by culturing ABC-reactive CD8+ T cells with feeders at a 1:4 ratio. When indicated, mAb or CTLA-4-Ig (ORENCIA [abatacept], Bristol-Myers Squibb) were added to cultures.

Treatment of mice. WT and/or HLA-B*57:01-Tg mice were injected i.p., 5 days a week for up to 4 weeks, with 3 mg ABC solution prepared as described in the Supplemental Methods section. In vitro culture assays. To facilitate the development of a cutaneous reaction, both ears were painted as indicated in Supplemental Figure 3 with a solution of 0.2 mg/ear of ABC, for up to 4 weeks. To deplete CD4+ T cells, the animals were injected i.p. with 0.25 mg anti-CD4 mAb (clone GK1.5, BioXcell) (Supplemental Figure 3B). To block PD-1 in vivo, 0.2 mg anti–PD-1 mAb was administered by i.p. injection (clone RPM1-14, BioXcell). In vivo neutralization of CD86 and/or CD80 was achieved by treating animals with CTLA-4-Ig (ORENCIA [abatacept], Bristol-Myers Squibb) or anti-CD80 mAb (clone 1G10, BioXcell) as specified in the Supplemental Methods. In preliminary experiments, the isotype control Abs were used in the control treatment groups.

Assessment of skin reaction on treated ears. Vehicle- or ABC-painted ears of WT and/or HLA-B*57:01-Tg animals were examined daily for signs of skin hypersensitivity and were photographed (EOS Rebel T5, Canon). Ear skin biopsy samples were used for histological and gene expression analyses as detailed in the Supplemental Methods.

Flow cytometry, cell sorting, and in vivo proliferation assays. Flow cytometry was used for the genotyping of mice, immune cell subset analysis by intracellular and/or surface marker staining, in vivo proliferation assays of CD8+ T lymphocytes, and CD8+ T cell sorting, as further detailed in the Supplemental Methods.

CD4+ and CD8+ T lymphocytes were pregated on singlet live CD3− cells; B cells were pregated on singlet CD3+ cells and identified as B220+CD19−; CD11c+MHC-II− DCs were pregated on singlet live cells and identified as CD11c+I-A− after gating out the CD3+ and CD19+ cells; and the DC subpopulation of XCR1+ cells was pregated on singlet live CD11c+I-A+ cells. NanoString sample preparation and data analysis. NanoString nCounter gene expression profiling was performed on CD8+ T lymphocytes sorted from LN cells of individual mice treated for up to 10 days, as detailed in the Methods section. After sorting, total RNA was extracted and hybridized with CodeSet and ProbeSet for 561 genes in the nCounter Mouse Immunology Panel plus 30 additional genes in a custom nCounter Panel-Plus and CodeSet-Plus (Supplemental Table 4) (all from Nanostring Technologies), according to the manufacturer’s instructions. Details on the data analysis including gene set enrichment analysis (GSEA) are provided in the Supplemental Methods.

Statistics. Statistical analyses were performed using an unpaired, 2-tailed Student’s t test and 2-way or 1-way ANOVA with Tukey’s multiple comparisons correction (GraphPad Prism 7.02, GraphPad Software). NanoString data analysis was performed using a 2-tailed Student’s t test with Welch’s correction (nSolver, version 3.0; NanoString Technologies). A P value of less than 0.05 was considered statistically significant.

Study approval. All experiments involving live animals were performed in accordance with the guidelines set forth in the Public Health Service Policy on the Humane Care and Use of Laboratory Animals and were approved by the IACUCs of the US FDA (protocol number 2017-11) and the NIAID, NIH (protocol number L140).

Author contributions. MC, MP, DHM, and MAN conceived, planned, and supervised the experiments. MET, LFB, KN, and DHM generated the HLA-B*57:01-Tg mice. MC, MP, KG, MET, and SG performed experiments. MY, GR, ADA, LJ, EM, and SA provided technical help. MC and MP analyzed the data. MC prepared the final figures and wrote the manuscript. MC, MP, KN, DHM, and MAN edited and reviewed the manuscript.

Acknowledgments. We thank Janet Woodcock, Director of the Center for Drug Evaluation and Research (CDER, FDA) for her continued support of this project. The authors wish to thank Jill Ascher, Mary Belcher, and the personnel of the animal facility of the US FDA’s Division of Veterinary Medicine for care of the mice. We also thank Hugh McFarland (CDER, FDA) for help with cell irradiation, Mark Kukuruga and the Center for Biologics Evaluation and Research flow cytometry core facility at the FDA White Oak campus for help with cell sorting, and Ethan M. Shevach (National Institute of Allergy and Infectious Diseases, NIH) for his comments on the manuscript. This work was supported by the FDA Intramural Research Program. DHM’s group is supported by the Intramural Research Program of the NIAID, NIH.

Address correspondence to: Marco Cardone, DBRR III/OBP/OPQ/CDER, U.S. Food and Drug Administration, 10903 New Hampshire Avenue, Silver Spring, Maryland 20993, USA. Phone: 240.402.9419; Email: Marco.Cardone@fda.hhs.gov. David H. Margulies, Laboratory of Immune System Biology, NIAID, National Institutes of Health, 9000 Rockville Pike, Bethesda, Maryland 20892, USA. Phone: 301.496.6429; Email: DMARGULIES@niaid.nih.gov. Michael A. Norcross, DBRR III/OBP/OPQ/CDER, U.S. Food and Drug Administration, 10903 New Hampshire Avenue, Silver Spring, Maryland 20993, USA. Phone: 240.402.8338; Email: michael.norcross@fda.hhs.gov.

MET’s present address is: Office of AIDS Research, DPCPSI, OD, NIH, Bethesda, Maryland, USA.


